The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders.

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders. But the drug does have ...

One of DOGE's engineers dispatched to take over the Education Department used to have a very different title: ketamine dealer ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Coalition Senator Jacinta Nampijinpa Price has opened up about her abuse of drugs and alcohol, and what ultimately drove her ...

Harvard researchers have found that M. morganii may contribute to depression by producing an inflammatory molecule.

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

The FDA approved 16 psychiatric drugs over the last decade, most of which shared similar mechanisms of action with previously ...

Green, who was coming off a year-long suspension in 2010 after testing positive for marijuana, tested positive for marijuana ...

Naloxone is a fantastic tool in reducing opioid deaths, but gentler versions would be helpful for fighting overdose ...